<?xml version="1.0" encoding="UTF-8"?>
<mods xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
      version="3.7"
      xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-7.xsd">
   <titleInfo>
      <title>Increased phosphorylation of HexM improves lysosomal uptake and potential for managing GM2 gangliosidoses</title>
   </titleInfo>
   <name type="personal" usage="primary">
      <namePart type="given">Graeme</namePart>
      <namePart type="family">Benzie</namePart>
      <displayForm>Benzie, Graeme</displayForm>
      <affiliation>Department of Microbiology, University of Manitoba, Winnipeg, Canada, R3T 2N2</affiliation>
      <role>
         <roleTerm type="text">author</roleTerm>
      </role>
   </name>
   <name type="personal">
      <namePart type="given">Kristen</namePart>
      <namePart type="family">Bouma</namePart>
      <displayForm>Bouma, Kristen</displayForm>
      <affiliation>Department of Microbiology, University of Manitoba, Winnipeg, Canada, R3T 2N2</affiliation>
      <role>
         <roleTerm type="text">author</roleTerm>
      </role>
   </name>
   <name type="personal">
      <namePart type="given">Taylor</namePart>
      <namePart type="family">Battellino</namePart>
      <displayForm>Battellino, Taylor</displayForm>
      <affiliation>Department of Chemistry, University of Manitoba, Winnipeg, Canada, R3T 2N2</affiliation>
      <role>
         <roleTerm type="text">author</roleTerm>
      </role>
   </name>
   <name type="personal">
      <namePart type="given">Steven</namePart>
      <namePart type="family">Cooper</namePart>
      <displayForm>Cooper, Steven</displayForm>
      <affiliation>Biochemistry and Medical Genetics; University of Manitoba</affiliation>
      <role>
         <roleTerm type="text">author</roleTerm>
      </role>
   </name>
   <name type="personal">
      <namePart type="given">Rick</namePart>
      <namePart type="family">Hemming</namePart>
      <displayForm>Hemming, Rick</displayForm>
      <affiliation>Biochemistry and Medical Genetics; University of Manitoba</affiliation>
      <role>
         <roleTerm type="text">author</roleTerm>
      </role>
   </name>
   <name type="personal">
      <namePart type="given">Wafa</namePart>
      <namePart type="family">Kammouni</namePart>
      <displayForm>Kammouni, Wafa</displayForm>
      <affiliation>Biochemistry and Medical Genetics; University of Manitoba</affiliation>
      <role>
         <roleTerm type="text">author</roleTerm>
      </role>
   </name>
   <name type="personal">
      <namePart type="given">Lin</namePart>
      <namePart type="family">Liu</namePart>
      <displayForm>Liu, Lin</displayForm>
      <affiliation>M6P Therapeutics, 20 S. Sarah St., St. Louis, MO, 63018, USA</affiliation>
      <role>
         <roleTerm type="text">author</roleTerm>
      </role>
   </name>
   <name type="personal">
      <namePart type="given">Cuong</namePart>
      <namePart type="family">Do</namePart>
      <displayForm>Do, Cuong</displayForm>
      <affiliation>M6P Therapeutics, 20 S. Sarah St., St. Louis, MO, 63018, USA</affiliation>
      <role>
         <roleTerm type="text">author</roleTerm>
      </role>
   </name>
   <name type="personal">
      <namePart type="given">Mazdak</namePart>
      <namePart type="family">Khajehpour</namePart>
      <displayForm>Khajehpour, Mazdak</displayForm>
      <affiliation>Department of Chemistry, University of Manitoba, Winnipeg, Canada, R3T 2N2</affiliation>
      <role>
         <roleTerm type="text">author</roleTerm>
      </role>
   </name>
   <name type="personal">
      <namePart type="given">Helene</namePart>
      <namePart type="family">Perreault</namePart>
      <displayForm>Perreault, Helene</displayForm>
      <affiliation>Department of Chemistry, University of Manitoba, Winnipeg, Canada, R3T 2N2</affiliation>
      <role>
         <roleTerm type="text">author</roleTerm>
      </role>
   </name>
   <name type="personal">
      <namePart type="given">Stuart</namePart>
      <namePart type="family">Kornfeld</namePart>
      <displayForm>Kornfeld, Stuart</displayForm>
      <affiliation>Washington University School of Medicine in St. Louis, Department of Biochemistry &amp; Molecular Biophysics</affiliation>
      <role>
         <roleTerm type="text">author</roleTerm>
      </role>
   </name>
   <name type="personal">
      <namePart type="given">Barbara</namePart>
      <namePart type="family">Triggs-Raine</namePart>
      <displayForm>Triggs-Raine, Barbara</displayForm>
      <affiliation>Biochemistry and Medical Genetics; University of Manitoba</affiliation>
      <role>
         <roleTerm type="text">author</roleTerm>
      </role>
   </name>
   <name type="personal">
      <namePart type="given">Brian L.</namePart>
      <namePart type="family">Mark</namePart>
      <displayForm>Mark, Brian L.</displayForm>
      <affiliation>Department of Microbiology, University of Manitoba, Winnipeg, Canada, R3T 2N2</affiliation>
      <role>
         <roleTerm type="text">author</roleTerm>
      </role>
   </name>
   <typeOfResource>text</typeOfResource>
   <genre>article</genre>
   <originInfo>
      <dateIssued encoding="w3cdtf" keyDate="yes">2021</dateIssued>
   </originInfo>
   <language>
      <languageTerm type="code" authority="iso639-2b">eng</languageTerm>
      <languageTerm type="text">English</languageTerm>
   </language>
   <abstract>Tay-Sachs and Sandhoff diseases are genetic disorders resulting from mutations in HEXA or HEXB, which code for the α- and β-subunits of the heterodimer β-hexosaminidase A (HexA), respectively. Loss of HexA activity results in the accumulation of GM2 ganglioside (GM2) in neuronal lysosomes, culminating in neurodegeneration and death, often by age 4. Previously, we combined critical features of the α- and β-subunits of HexA into a single subunit to create a homodimeric enzyme known as HexM. HexM is twice as active as HexA and degrades GM2 in vivo, making it a candidate for enzyme replacement therapy (ERT). Here we show HexM production is scalable to meet ERT requirement and we describe an approach that enhances its cellular uptake via co-expression with an engineered GlcNAc-1-phosphotransferase that highly phosphorylates lysosomal proteins. Further, we developed a HexA overexpression system and functionally compared the recombinant enzyme to HexM, revealing the kinetic differences between the enzymes. This study further advances HexM as an ERT candidate and provides a convenient system to produce HexA for comparative studies. </abstract>
   <note type="admin">Pre-press version</note>
   <relatedItem type="host">
      <titleInfo>
         <title>BBA Advances</title>
      </titleInfo>
      <originInfo>
         <publisher>Elsevier B.V.</publisher>
      </originInfo>
      <identifier type="issn">2667-1603</identifier>
      <part>
         <text type="year">2021</text>
         <extent unit="pages">
            <start>100032</start>
         </extent>
      </part>
   </relatedItem>
   <identifier type="doi">10.1016/j.bbadva.2021.100032</identifier>
   <location>
      <url>http://dx.doi.org/10.1016/j.bbadva.2021.100032</url>
   </location>
   <identifier type="pii">S2667-1603(21)00031-4</identifier>
   <accessCondition type="use and reproduction"
                    displayLabel="Creative Commons Attribution 4.0 Generic (CC BY-NC-ND 4.0)">
      <program xmlns="https://data.crossref.org/schemas/AccessIndicators.xsd">
         <licence_ref applies_to="reuse" start_date="2021-12-09"/>
         <licence_ref>http://creativecommons.org/licenses/by-nc-nd/4.0/</licence_ref>
      </program>
   </accessCondition>
   <extension>
      <vendorName/>
      <archiveFile/>
      <originalFile>file:/C:/Users/Carlos.Martinez/OneDrive%20-%20USDA/XML_projects/OpenAccess/OpenAccess/transform/source/sourcefiles/164128545923847224-00001/2667-1603/aip/S2667160321000314/S2667160321000314.xml</originalFile>
      <workingDirectory>C:\Users\Carlos.Martinez\OneDrive - USDA\XML_projects\OpenAccess\OpenAccess\transform\result\</workingDirectory>
   </extension>
</mods>
